Zynbrita a New Treatment Available for Relapsing Multiple Sclerosis

In the News: June 2016 - FDA Approvals, News & Updates

On May 27, 2016, the FDA approved daclizumab (Zinbryta; Biogen), a long-acting injection, for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab can be self-administered by the patient.  Daclizumab is recommended for patients who had an inadequate response to ≥2 drugs for MS, because of its safety profile.

Daclizumab was approved for relapsing MS based on 2 double-blind, controlled clinical trials that used 150 mg daclizumab, administered once monthly. The first trial compared daclizumab with interferon beta-1a (Avonex) in 1841 patients with relapsing MS. The daclizumab group had a 45% relapse reduction and a 54% reduction in new or enlarging T2- hyperintense lesions versus the interferon beta-1a group. The second study compared daclizumab with placebo in 412 patients with relapsing MS. Daclizumab had a 54% relapse reduction, a 57% reduction in disease progression, a 70% reduction in new or newly enlarging T2-hyperintense lesions, and a 69% reduction in new T1 Gd-enhancing lesions versus interferon beta-1a. Of note, 81% of patients using daclizumab were relapse free compared with 64% in the interferon beta-1a group.

The most common adverse events reported with daclizumab in the 2 studies included nasopharyngitis, upper respiratory tract infection, eczema, rash, influenza, dermatitis, depression, oropharyngeal pain, lymphadenopathy, and increased alanine aminotransferase levels.

Daclizumab was approved with a boxed warning about the serious risk for hepatic injury, including autoimmune hepatitis and other immune-mediated disorders. Transaminase and bilirubin levels should be evaluated before starting daclizumab therapy, and patients should be monitored monthly and up to 6 months after stopping therapy. Daclizumab is distributed through a Risk Evaluation and Mitigation Strategy program only.

Related Items
Welcome to the Ninth Annual Payers’ Guide to New FDA Approvals
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 12, 2018 in FDA Approvals, News & Updates
FDA Approvals in 2017 Represent a 21-Year High
Gary M. Owens, MD
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 11, 2018 in FDA Approvals, News & Updates
FDA Approvals of Brand-Name Prescription Drugs in 2017
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 11, 2018 in FDA Approvals, News & Updates
Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 10, 2018 in FDA Approvals, News & Updates
Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 10, 2018 in FDA Approvals, News & Updates
Last modified: June 20, 2016
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME